Incorporating New Therapies to Hone the Treatment of Resistant or Refractory CMV in the Post-SOT Setting: Proceedings from a Clinical Olympics

Program Overview

Join Drs. Kotton, Pereira, and Razonable as they discuss the management of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. Topics covered include treatment challenges, laboratory testing, and new therapy for refractory or resistant CMV.

Credit Expired

Target Audience

Infectious disease, transplantation, internal medicine, and pharmacy clinicians managing patients with CMV

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply treatment strategies with established antiviral therapies to solid organ transplant (SOT) recipients who develop cytomegalovirus (CMV) in the post-transplant setting
  • Identify SOT recipients who develop treatment-resistant or refractory CMV in the post-transplant setting
  • Integrate new antiviral therapies into management regimens for resistant or refractory CMV in the post-SOT setting

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Associate Professor, Medicine
Harvard Medical School
Boston, MA

62-23-1044-SM-002 ATC 2023-Faculty Photo Marcus_Pereira 1200X1500

Marcus R. Pereira, MD, MPH, FAST

Associate Professor, Medicine
Medical Director, Transplant Infectious Diseases Program
Columbia University Irving Medical Center
NewYork Presbyterian Hospital
New York, NY


Raymund R. Razonable, MD, FIDSA, FAST 

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, MN



Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources